New nicotinamide–thiadiazol hybrids as VEGFR-2 inhibitors for breast cancer therapy: design, synthesis and in silico and in vitro evaluation
RSC Advances · 2025 · 15 (18) · 14477-14498
DOI: 10.1039/d5ra01223f ↗Kurz gefasst
Fachartikel in der Zeitschrift RSC Advances, 2025. Verfasst von Walid E Elgammal und 9 weiteren Autor:innen. Beteiligte Einrichtung: Chemistry Department, Faculty of Science, Al-Azhar University Nasr City 11884, Cairo Egypt. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: AlMaarefa University, Princess Nourah Bint Abdulrahman University.
Abstract (Originalsprache)
Vascular endothelial growth factor receptor-2 (VEGFR-2) is a key regulator of tumor angiogenesis and has become an important target in anticancer drug development.
Autor:innen und Institutionen
- Chemistry Department, Faculty of Science, Al-Azhar University Nasr City 11884, Cairo Egypt.
- Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University Cairo 11884 Egypt Ibrahimeissa@azhar.edu.eg Hazemelkady@azhar.edu.eg.
- Pharmaceutical Chemistry Department, Faculty of Pharmacy, Merit University Sohag 82755 Egypt.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University P. O. Box 33516 Kafrelsheikh Egypt.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Pharos University in Alexandria Canal El Mahmoudia Street Alexandria 21648 Egypt.
- Chemistry Department, Faculty of Science, New Valley University El-Kharja 72511 Egypt.
ORCID-Profile: Walid E Elgammal, Hazem Elkady, Wagdy M Eldehna, Eslam B Elkaeed, Ibrahim H Eissa, Ahmed M Metwaly
Förderung
- AlMaarefa University
- Princess Nourah Bint Abdulrahman University
Zitieren
APA
Elgammal, W. E., Elkady, H., Yousef, R. G., Eldehna, W. M., Husein, D. Z., Amin, F. G., Alsfouk, B. A., Elkaeed, E. B., Eissa, I. H., & Metwaly, A. M. (2025). New nicotinamide–thiadiazol hybrids as VEGFR-2 inhibitors for breast cancer therapy: design, synthesis and in silico and in vitro evaluation. RSC Advances, 15(18), 14477-14498. https://doi.org/10.1039/d5ra01223f
Vancouver
Elgammal WE, Elkady H, Yousef RG, Eldehna WM, Husein DZ, Amin FG, et al. New nicotinamide–thiadiazol hybrids as VEGFR-2 inhibitors for breast cancer therapy: design, synthesis and in silico and in vitro evaluation. RSC Advances. 2025;15(18):14477-14498. doi:10.1039/d5ra01223f
BibTeX
@article{Elgammal2025,
author = {Elgammal, Walid E and Elkady, Hazem and Yousef, Reda G and Eldehna, Wagdy M and Husein, Dalal Z and Amin, Fatma G and Alsfouk, Bshra A and Elkaeed, Eslam B and Eissa, Ibrahim H and Metwaly, Ahmed M},
title = {New nicotinamide–thiadiazol hybrids as VEGFR-2 inhibitors for breast cancer therapy: design, synthesis and in silico and in vitro evaluation},
journal = {RSC Advances},
year = {2025},
volume = {15},
number = {18},
pages = {14477--14498},
doi = {10.1039/d5ra01223f}
}
EUVIMED